Coya Therapeutics’ (COYA) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research report released on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $15.00 target price on the stock.

A number of other analysts also recently commented on the company. BTIG Research increased their price target on Coya Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Lake Street Capital restated a “buy” rating and issued a $17.00 price objective on shares of Coya Therapeutics in a research note on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, October 8th. Chardan Capital reissued a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a report on Friday, November 14th. Finally, HC Wainwright restated a “buy” rating on shares of Coya Therapeutics in a research report on Monday, November 24th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Coya Therapeutics Price Performance

COYA opened at $5.52 on Tuesday. Coya Therapeutics has a fifty-two week low of $4.65 and a fifty-two week high of $8.29. The firm has a market capitalization of $115.39 million, a PE ratio of -4.97 and a beta of 0.20. The company’s 50-day moving average is $6.06 and its 200 day moving average is $6.05.

Coya Therapeutics (NASDAQ:COYA) last posted its earnings results on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.12). Coya Therapeutics had a negative return on equity of 55.76% and a negative net margin of 462.24%.The firm had revenue of $3.56 million during the quarter, compared to the consensus estimate of $3.70 million. As a group, analysts expect that Coya Therapeutics will post -1.15 EPS for the current year.

Hedge Funds Weigh In On Coya Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Prosperity Wealth Management Inc. raised its position in shares of Coya Therapeutics by 16.4% in the third quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock valued at $136,000 after purchasing an additional 3,350 shares during the period. JPMorgan Chase & Co. bought a new position in Coya Therapeutics in the 3rd quarter worth approximately $28,000. Charles Schwab Investment Management Inc. purchased a new position in Coya Therapeutics in the 1st quarter valued at approximately $65,000. Lantern Wealth Advisors LLC bought a new stake in Coya Therapeutics during the 3rd quarter valued at $66,000. Finally, Jane Street Group LLC lifted its position in shares of Coya Therapeutics by 101.7% during the first quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock worth $169,000 after acquiring an additional 13,176 shares in the last quarter. Institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.